Recent Study: Global Multiple Myeloma Drugs Market 2015-2019

Multiple myeloma is a common cancer that affects the plasma cells, a type of white blood cell. It begins in the plasma cells of bone marrow. The primary function of the plasma cells is to combat infections by producing antibodies, which attack germs after recognizing them. In multiple myeloma these plasma cells become malignant, it causes the production of a defective protein, which grows uncontrollably. This protein moves into the bones and cause tumors. Myeloma occurs when the malignant cells form a tumor. According to the Multiple Myeloma Research Foundation, the disease has been classified into six distinct stages: Pain in bone, vulnerability to infections, increased restlessness, kidney and urination ailments, fatigue, increase in thirst, loss of appetite and loss in weight. The disease can be diagnosed by a series of tests. The initial evaluation consists of a blood test, urine test and a bone marrow biopsy. X-ray, MRI scan, CT- scan and PET scan are other tests to diagnose multiple myeloma. Genomic testing is also carried out to confirm the presence of multiple myeloma in the suspected patients.

Full Report Details at
- http://www.fastmr.com/prod/933060_global_multiple_myeloma_drugs_market_20152019.aspx?afid=301

TechNavio's analysts forecast the Global Multiple Myeloma Drugs market to grow at a CAGR of 8.50 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Multiple Myeloma Drugs market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various generic and branded therapies used in the treatment of multiple myeloma.

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Multiple Myeloma Drugs market. In addition, the report discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

Key Regions

* Americas
* APAC
* EMEA

Key Vendors

* Celgene
* Johnson & Johnson
* Novartis
* Onyx Pharmaceuticals
* Sanofi
* Takeda Pharmaceutical

Other Prominent Vendors

* AB Science
* Abbvie
* Aeterna Zentaris
* Amgen
* Bristol Myers Squibb
* Cephalon
* Daiichi Sankyo
* Genta
* Merck Sharp and Dohme
* Oncotherapeutics
* PharmaMar
* Teva

Market Driver

* Presence of Unmet Needs
* For a full, detailed list, view our report

Market Challenge

* High Cost of Treatment
* For a full, detailed list, view our report

Market Trend

* Growing Public Awareness
* For a full, detailed list, view our report

Key Questions Answered in this Report

* What will the market size be in 2019 and what will the growth rate be?

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Multiple Myeloma (Kahler's Disease) Global Clinical Trials Review, H2, 2014
- Refractory Multiple Myeloma Global Clinical Trials Review, H2, 2014
- Relapsed Multiple Myeloma Global Clinical Trials Review, H2, 2014
- Multiple Myeloma (Kahler's Disease) - Pipeline Review, H2 2014
- Relapsed Multiple Myeloma - Pipeline Review, H2 2014